Developing technologies and therapies for infectious diseases

Spurred by the pandemic response, a new wave of vaccine technologies is poised to expand a menu of prophylactic options.

Clinical stage company Evaxion Biotech is using artificial intelligence (AI) to simulate the immune system and create predictive models to identify novel targets for vaccines against bacterial and viral diseases and immunotherapies for cancer.

Vaccination saves two to three million lives annually. GSK will continue delivering proven vaccines, expand their availability to populations in need, and create new vaccines to protect against endemic and emerging diseases. To those who possess novel technologies that can innovate vaccine creation, GSK ventures to be your partner of choice.

Achelois developed molecular velcro-based antiviral technology to build next-generation therapeutics to pre-empt emerging pandemic viruses.

The evolution of antifungal resistance is undermining the armamentarium of antifungal therapeutics and threatens novel agents coming through the pipeline. F2G, an antifungal-focused biopharma company, is addressing the need for medicines to treat fungal infections, which is hard but not insurmountable.

SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its proprietary immunotherapies show promise for treating and preventing infectious diseases and autoimmune and oncological disorders.

Attivare Therapeutics is developing vaccines that offer an amplified humoral and cellular immune response to target infectious diseases with a single-shot option.